Vla-4' e bağlı hücre bağlamasının peptidilsiz önleyicileri

Adi geçen bilesiklerin iltihabik, otoimün ve solunum hastaliklkarinin tedavisinde faydali VLA-4 önleyicileri olduklari ve adi geçen bilesiklerin formül (1.0.0)' a ait bir bilesik ihtiva ettigi peptidilsiz bilesiklerin bir cinsi ve bunlarin farmasötik açidan kabul gören tuzlari ve baska ön ilaç...

Full description

Saved in:
Bibliographic Details
Main Authors ALLEN JACOB DUPLANTIER, LOUIS STANLEY CHUPAK, WAN FANG LAU, ANTHONY JOHN MILICI
Format Patent
LanguageTurkish
Published 21.11.2002
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Adi geçen bilesiklerin iltihabik, otoimün ve solunum hastaliklkarinin tedavisinde faydali VLA-4 önleyicileri olduklari ve adi geçen bilesiklerin formül (1.0.0)' a ait bir bilesik ihtiva ettigi peptidilsiz bilesiklerin bir cinsi ve bunlarin farmasötik açidan kabul gören tuzlari ve baska ön ilaç türevleri sunulmustur. FORMÜL There is disclosed a genus of non-peptidyl compounds, wherein said compounds are VLA-4 inhibitors useful in treating inflammatory, autoimmune, and respiratory diseases, and wherein said compounds comprise a compound of Formula (1.0.0): and pharmaceutically acceptable salts and other prodrug derivatives thereof, wherein: A is (C1-C6) alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl optionally substituted with 0 to 3 R9; or is a member selected from the group consisiting of the following radicals: A1-NHC(-O)NH-A2-, A1-NHC(-O)O-A2-, A1-OC(-O)NH-A2-, A1-NHSO2NH-A2-, A1-NHC(-O)-A2-, A1-C(-O)NH-A2-, A1-NHSO2-A2-, A1-SO2NH-A2-, A1-(CH2)rO-A2-, A1-O(CH2)r-A2, A1-(CH2)r-A2-, where A1 and A2 are each independently selected from the group consisting of hydrogen, aryl, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, cycloalkyl, heteroaryl, and heterocyclyl substituted with 0 to 3 R9; B is a member independently selected from the group consisting of the following: E is a single bond; -O-; -NR10-; -CH-CH-; -CC-; S(-O)q; -CR11R12NR10-; or -CR11R12-; X is -O-; -C(-O)-; -S(-O)q-; or -NR10-; X1, X2 and X3 are each independently selected from the group consisting of CH, CR9 or N; Y is a single bond; -C(-O)-; -C(-S)-; or -S(-O)2-; R7 is (C1-C6) alkyl; (CH2)kOR5; (CH2)kNR6C(-O)R5; (CH2)kNR6C(-O)OR5; (CH2)kNR6SO2R5; (CH2)kNR6R5; F; CF3; OCF3; aryl, substituted with 0 to 3 R9; heterocyclyl, substituted with 0 to 3 R9; heteroaryl, substituted with 0 to 3 R9; cycloalkyl, substituted with 0 to 3 R9; or R7 may be taken together with R8 to form a cycloalkyl or heterocyclyl ring; or R7 may be taken together with R11 to form a cycloalkyl or heterocyclyl ring; and R8 is hydrogen; F; (C1-C6) alkyl or (C1-C6) alkoxy.
Bibliography:Application Number: TR20020001668T